Oh, no we aren’t! AbbVie says it isn’t rethinking pricing pledge at all
Late last week Leerink’s Geoffrey Porges caused quite a stir when he outlined a recent sit-down with the top execs at AbbVie. With the brouhaha over drug pricing at the beginning of the year settling down, Porges said CEO Rick Gonzalez and CFO Bill Chase sounded like they were beginning to waffle over their pledge to limit price hikes on Humira to the single digits, once a year — breaking from a steady drive of price increases that has made Humira into a massive blockbuster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.